OFIX

Business Context and Reporting Period

Company: Orthofix International N.V. (Orthofix)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 1998
Business Overview: Orthofix designs, manufactures, and markets medical equipment for the orthopedic market, primarily external/internal fixation devices and pulsed electromagnetic frequency (PEMF) products for bone healing. Operations are conducted through subsidiaries in the U.S., Italy, U.K., and other international markets.

Key Financial Metrics

Note: 1998 Net Income includes a one-time gain of $8.1 million from the sale of a product license and a $3.3 million impairment charge. Adjusted Net Income (excluding non-recurring items) was $9.5 million.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 16% driven by 19% growth in North America (primarily PEMF and Fixation products) and 11% growth internationally (driven by A-V Impulse System and Laryngeal Mask).
• Profitability Surge: Net income increased significantly due to a $9.7 million gross gain (net $8.1 million) from licensing the BoneSource technology to Howmedica, Inc., and a reduction in the effective tax rate from 45% to 33% (due to lower non-deductible litigation costs and Italian tax rate reductions).
• Debt Reduction: Total debt decreased by approximately $10.7 million as the company used operating cash flows and license proceeds to repay long-term debt.
• Impairment Charges: The company recorded a $3.3 million write-off of intangible assets related to the "Ogden Anchor" product due to disappointing sales and a $1.6 million goodwill write-down related to BoneSource.
• Expense Management: General and administrative expenses decreased by $400,000, largely due to a reduction in litigation costs from $2.0 million in 1997 to $369,000 in 1998.

Guidance, Outlook, and Risks

• Legal Contingency: A significant pending appeal involves a 1997 jury verdict awarding Orthofix $98.9 million in damages against EBI Medical Systems, Inc. The appeal was heard in October 1998, with a decision expected in 1999. The financial statements do not reflect this potential gain.
• Product Strategy: The company discontinued further investment in the Ogden Anchor product. It continues to expand PEMF product lines (Spinal-Stim, Physio-Stim) and has secured distribution agreements for BoneSource with Howmedica.
• Liquidity: Management believes current cash balances and projected cash flows are sufficient to cover capital needs and R&D costs for the next two fiscal years. The company has an $18 million credit facility ($15M term note, $3M revolver).
• Year 2000 Compliance: The company has spent $350,000 to date on Y2K compliance, with an estimated additional $150,000 required in 1999. Management does not anticipate material disruption.
• Regulatory Risks: Operations are subject to FDA and foreign regulatory approvals. The company maintains compliance but notes risks associated with reimbursement policies from third-party payors.

Investor Verification Checklist

• EBI Litigation Outcome: Verify the final resolution of the $98.9 million appeal against EBI Medical Systems, Inc., as this represents a material potential asset not currently booked.
• BoneSource Licensing: Confirm the ongoing royalty revenue stream and market performance of BoneSource under the Howmedica distribution agreement.
• PEMF Reimbursement: Monitor third-party payor reimbursement rates for PEMF products (Spinal-Stim/Physio-Stim), which are critical to the 41% revenue segment.
• Debt Covenants: Review compliance with the $18 million credit facility covenants, specifically the restrictions on asset transfers from Orthofix Inc. to the parent company.
• Y2K Costs: Track actual Year 2000 compliance costs against the estimated $150,000 remaining budget to ensure no unexpected overruns.